鍏充簬EMPA-REG OUTCOME^{®<\/sup><\/b>2<\/sup><\/b>,<\/sup><\/b>3<\/sup><\/b> <\/p> \n}

EMPA-REG OUTCOME®鏄竴椤归暱鏈熴€佸浗闄呫€侀殢鏈恒€佸弻鐩层€佸畨鎱板墏瀵圭収涓村簥璇曢獙锛屽叆閫変簡7,000澶氬悕鏉ヨ嚜42涓浗瀹剁‘璇婃湁蹇冭绠＄梾鐨処I鍨嬬硸灏跨梾鎮ｈ€呫€�<\/p> \n

鏈爺绌惰瘎浼颁簡涓庡湪鏍囧噯鐤楁硶鍩虹涓婂姞鐢ㄥ畨鎱板墏鐨勬儏鍐电浉姣旓紝鍦ㄦ爣鍑嗙枟娉曞熀纭€涓婂姞鐢ㄦ仼鏍煎垪鍑€锛�10 mg鎴�25 mg姣忔棩涓€娆★級鐨勭枟鏁堛€傛爣鍑嗙枟娉曠敱闄嶇硸鑽墿鍙婂績琛€绠¤嵂鐗╋紙鍖呮嫭闄嶅帇鑽強璋冭剛鑽級缁勬垚銆備富瑕佺粓鐐瑰畾涔変负鑷抽娆″彂鐢熷績琛€绠℃浜°€侀潪鑷存鎬у績鑴忕梾鍙戜綔鎴栭潪鑷存鎬у崚涓殑鏃堕棿銆�<\/p> \n

鎭╂牸鍒楀噣鍦‥MPA-REG OUTCOME^{®<\/sup>璇曢獙涓殑鏁翠綋瀹夊叏鎬х壒寰佷笌姝ゅ墠涓村簥璇曢獙鎵€瑙傚療鍒扮殑缁撴灉涓€鑷淬€�<\/p> \n}

鍏充簬蹇冨姏琛扮<\/b><\/p> \n

蹇冨姏琛扮鏄績鑴忔棤娉曞悜韬綋娉靛嚭瓒抽噺琛€娑叉椂鍙戠敓鐨勪竴绉嶈繘灞曟€с€佹秷鑰楁€х敋鑷冲彲鑳戒細鑷存鐨勭柧鐥呫€�^{[6]<\/sup><\/sup>蹇冨姏琛扮鐨勭棁鐘跺寘鎷懠鍚稿洶闅俱€佹诞鑲裤€佺柌涔忓強鍏朵粬鐥囩姸銆�[7]<\/sup><\/sup>蹇冨姏琛扮鏄竴绉嶆祦琛岀梾锛涘湪涓栫晫鑼冨洿鍐咃紝鎱㈡€у績鍔涜“绔殑鎮ｈ€呮暟宸茶揪鍒颁簡2600涓囦汉銆�[8]<\/sup><\/sup>鐢变簬绾︽湁50%鐨勭‘璇婂績鍔涜“绔偅鑰呭皢浼氬湪浜斿勾鍐呮浜★紝鍥犳鍦ㄥ蹇冨姏琛扮鐨勬不鐤楁柟闈㈠瓨鍦ㄧ潃寰堥珮鐨勪簾寰呮弧瓒崇殑闇€姹傘€�[9]<\/sup><\/sup>姝ゅ锛屽績鍔涜“绔篃鏄缇�65宀佸強浠ヤ笂浜虹兢涓渶甯歌鐨勪綇闄㈠師鍥犮€�10<\/sup>蹇冨姏琛扮鍦ㄧ硸灏跨梾鎮ｈ€呬腑鍙戠梾鐜囧緢楂橈紱[10]<\/sup><\/sup> 鐒惰€岋紝鍦ㄦ墍鏈夊績琛版偅鑰呬腑绾︽湁鍗婃暟骞舵湭鎮ｆ湁绯栧翱鐥呫€�10<\/sup>,<\/sup>[11]<\/sup><\/sup><\/p> \n}

鍏充簬鎱㈡€ц偩鐥�<\/b><\/p> \n

鎱㈡€ц偩鐥呭畾涔変负闅忔椂闂存帹绉昏偩鍔熻兘杩涜鎬у噺閫€鐨勭柧鐥呫€� <\/p> \n

绾︽湁涓夊垎涔嬩簩鐨勬參鎬ц偩鐥呭彲褰掑洜浜庣硸灏跨梾銆佽偉鑳栧強楂樿鍘嬬瓑浠ｈ阿鎬х柧鐥呫€�^{[12]<\/sup><\/sup>,<\/sup>[13]<\/sup><\/sup>,<\/sup>[14]<\/sup><\/sup><\/p> \n}

鍊煎緱娉ㄦ剰鐨勬槸锛屾參鎬ц偩鐥呬細澧炲姞鎮ｈ€呯殑鎮ｇ梾鐜囧強姝讳骸鐜囥€傛參鎬ц偩鐥呮偅鑰呬富瑕佺殑姝讳骸鍘熷洜涓哄績琛€绠″苟鍙戠棁锛屽苟涓旈€氬父閮戒細鍦ㄨ揪鍒扮粓鏈湡鑲剧梾涔嬪墠鍙戠敓銆�^{[15]<\/sup><\/sup>,<\/sup>[16]<\/sup><\/sup>,<\/sup>[17]<\/sup><\/sup> 涓€鏃﹁繘灞曚负缁堟湯鏈熻偩鐥咃紝鍒欏彈绱釜浣撳繀椤昏繘琛岄暱鏈熼€忔瀽鎴栬偩绉绘绛夎偩鏇夸唬娌荤枟銆�[18]<\/sup><\/sup>鎱㈡€ц偩鐥呭湪涓栫晫鍚勫湴閮介珮鍙戯紝鎮ｇ梾浜烘暟瓒呰繃浜嗕汉鍙ｆ暟閲忕殑10%[19]<\/sup><\/sup>銆傞壌浜庣洰鍓嶈繕娌℃湁鐤楁硶琚壒鍑嗕笓鐢ㄤ簬鍑忕紦鑲剧梾杩涘睍銆侀檷浣庡績琛€绠℃浜＄巼锛屽湪鏁翠綋涓婃參鎬ц偩鐥呮偅鑰呭浜庢柊鐨勭枟娉曟樉鐒舵湁鐫€浜熷緟婊¤冻鐨勫尰鐤楅渶姹傘€�<\/p> \n}

鍏充簬鎭╂牸鍒楀噣<\/b>
<\/p> \n

鎭╂牸鍒楀噣锛堝晢鍝佸悕涓烘鍞愰潤^{®<\/sup>锛夋槸涓€绉嶆瘡鏃ヤ竴娆″彛鏈嶇粰鑽殑楂橀€夋嫨鎬ч挔-钁¤悇绯栬浆杩愪綋2锛圫GLT2锛夋姂鍒跺墏锛屽悓鏃朵篃鏄涓€绉嶅湪鑽搧璇存槑涔︿笂鍖呮嫭浜嗗彲闄嶄綆蹇冭绠℃浜￠闄╂暟鎹殑II鍨嬬硸灏跨梾娌荤枟鑽墿銆�[20]<\/sup>,[21],[22]<\/sup><\/p> \n}

鎭╂牸鍒楀噣瀵逛簬II鍨嬬硸灏跨梾鎮ｈ€匰GLT2浠ュ強楂樿绯栫殑鎶戝埗浣滅敤鑳藉淇冧娇澶氫綑鐨勭硸鍒嗛€氳繃灏挎恫鎺掑嚭浣撳銆傛澶栵紝鍚姩鎭╂牸鍒楀噣娌荤枟鑳藉澧炲姞浣撳唴鐩愬垎鐨勬帓鍑哄苟鍑忓皯鏈轰綋琛€绠＄郴缁熺殑浣撴恫璐熻嵎锛堝嵆琛€绠″唴瀹归噺锛夈€傛仼鏍煎垪鍑€璇卞浣撳唴绯栥€佺洂鍙婃按鐨勪唬璋㈠彂鐢熸敼鍙橈紝杩欏彲鑳戒笌EMPA-REG OUTCOME^{®<\/sup>璇曢獙涓墍瑙傚療鍒扮殑蹇冭绠℃浜＄巼闄嶄綆鐜拌薄瀛樺湪鍏宠仈鎬с€�<\/p> \n}

References<\/b><\/p> \n

^{[1] <\/sup><\/sup>Jardiance®<\/sup> (empagliflozin) Summary of Product Characteristics. EMA. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002677\/WC500168592.pdf<\/a>. Last accessed June 2018<\/span>.<\/p> \n}

[2] EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved).Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951?term=emperor&rank=2<\/a>. Last accessed: May 2018<\/span>.<\/p> \n

[3] EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced).Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977?term=emperor&rank=1.Last<\/a> accessed: May 2018<\/span>.<\/p> \n

[4] A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with preserved Ejection Fraction (HFpEF) (EMPERIAL 鈥� preserved).Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03448406?term=EMPERIAL&rank=1<\/a>. Last accessed: May 2018<\/span>.<\/p> \n

[5] A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with reduced Ejection Fraction (HFrEF) (EMPERIAL 鈥� reduced).Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03448419?term=EMPERIAL&rank=2<\/a> .Last accessed: May 2018<\/span>.<\/p> \n

^{[6]<\/sup><\/sup> American Heart Association.What is Heart Failure? Available at:} http:\/\/www.heart.org\/HEARTORG\/Conditions\/HeartFailure\/AboutHeartFailure\/What-is-Heart-Failure_UCM_002044_Article.jsp#.WleEeLSFjBI<\/a>. Last accessed May 2018<\/span>.<\/p> \n

^{[7] <\/sup><\/sup>Watson RDS, Gibbs CR, Lip GYH.Clinical features and complications.British Medical Journal.2000;320(7229):236-239.<\/p> \n}

^{[8]<\/span><\/sup> Ambrosy A.P., et al.The Global Health and Economic Burden of Hospitalizations for Heart Failure.J Am Coll Cardiol 2014.1;63(12):1123-1133.<\/p> \n}

^{[9]<\/sup><\/sup>Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al.Heart disease and stroke statistics鈥�2013 update: a report from the American Heart Association.Circulation.2013;127:e6鈥揺245<\/p> \n}

^{[10]<\/sup><\/sup> Yancy CW., et al.2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/ American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 62 (16), e147 - e239.<\/p> \n}

^{[11]<\/sup><\/sup> Suskin N, et al.Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.Eur Heart J 2000;21:1368-75.<\/p> \n}

^{[12] <\/sup><\/sup>Levin A, Tonelli M, Bonventre J, et al.Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.Lancet 2017;390:1888-917.<\/p> \n}

^{[13] <\/sup><\/sup>Liyanage T, Ninomiya T, Jha V, et al.Worldwide access to treatment for end-stage kidney disease: a systematic review.Lancet 2015; 385(9981):1975-82.<\/p> \n}

^{[14]<\/sup> United States Renal Data System, USRDS 2012 Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States<\/span>, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD<\/span>, 2012.Available from:} http:\/\/www.usrds.org\/reference.htm.See<\/a> Appendix I, United States Renal Data System (USRDS).<\/p> \n

^{[15] <\/sup><\/sup>Sarnak MJ, Levey AS, Schoolwerth AC, et al.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Hypertension 2003;42:1050-65. <\/p> \n}

^{[16] <\/sup><\/sup>Tonelli M, Wiebe N, Culleton B, et al.Chronic kidney disease and mortality risk: a systematic review.J Am Soc Nephrol.2006;17:2034-47. <\/p> \n}

^{[17] <\/sup><\/sup>Schiffrin EL, Lipman ML and Mann JFE.Chronic kidney disease: effects on the cardiovascular system.Circulation.2007;116:85-97. <\/p> \n}

^{[18]<\/span><\/sup> American Kidney Fund.Kidney Failure (ESRD) Causes, Symptos, & Treatments.Available at:} http:\/\/www.kidneyfund.org\/kidney-disease\/kidney-failure\/<\/a>. Accessed March 2018<\/span>.<\/p> \n

^{[19]<\/sup><\/sup> Eckardt K-U, Coresh J, Devuyst O, et al.Evolving importance of kidney disease: from subspecialty to global health burden.Lancet 2013;382:158-69.<\/p> \n}

^{[20]<\/sup><\/sup> Jardiance®<\/sup> (empagliflozin) tablets U.S. Prescribing Information.Available at:} http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf<\/a>. Accessed May 2018<\/span>.<\/p> \n

^{[21] <\/sup><\/sup>European Summary of Product Characteristics Jardiance®, approved January 19<\/span>, 2017.Data on file. <\/p> \n}

^{[22] <\/sup><\/sup>Jardiance®<\/sup> (Full Prescribing Information).Mexico<\/span>; Boehringer Ingelheim Pharmaceuticals, Inc; 2017.<\/p>"]; $("#dvExtra").html(content_array[0]);})();}